Lansforsakringar Fondforvaltning AB publ Buys Shares of 434 argenx SE (NASDAQ:ARGX)

Lansforsakringar Fondforvaltning AB publ acquired a new position in argenx SE (NASDAQ:ARGX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 434 shares of the company's stock, valued at approximately $267,000.

Several other hedge funds have also recently bought and sold shares of ARGX. SG Americas Securities LLC lifted its stake in argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock worth $220,000 after acquiring an additional 21 shares in the last quarter. Blue Trust Inc. lifted its stake in argenx by 46.2% in the 4th quarter. Blue Trust Inc. now owns 541 shares of the company's stock worth $333,000 after acquiring an additional 171 shares in the last quarter. Crews Bank & Trust purchased a new stake in argenx in the 4th quarter worth about $575,000. Keudell Morrison Wealth Management lifted its stake in argenx by 33.1% in the 4th quarter. Keudell Morrison Wealth Management now owns 507 shares of the company's stock worth $312,000 after acquiring an additional 126 shares in the last quarter. Finally, Caprock Group LLC purchased a new stake in argenx in the 4th quarter worth about $304,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Performance

Shares of NASDAQ ARGX traded down $7.99 during mid-day trading on Tuesday, reaching $576.61. 198,149 shares of the company traded hands, compared to its average volume of 323,278. The stock has a market cap of $35.21 billion, a PE ratio of -655.24 and a beta of 0.57. The company's fifty day moving average is $586.25 and its two-hundred day moving average is $612.53. argenx SE has a fifty-two week low of $368.57 and a fifty-two week high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Research analysts forecast that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ARGX shares. Citigroup reissued a "buy" rating on shares of argenx in a research note on Wednesday, May 21st. Wedbush reaffirmed an "outperform" rating and issued a $715.00 target price on shares of argenx in a research report on Friday, April 11th. Oppenheimer upped their target price on argenx from $704.00 to $708.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Sanford C. Bernstein raised argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Finally, Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $709.18.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.